Recruiting

Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study

POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.

ClinicalTrials.gov IDNCT06336070

PhaseNA

Enrollment56

SponsorUniversity of Valencia

Age35 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer Female, Cardiometabolic Syndrome, Metabolism Disorder, Lipid, Autonomic Dysfunction, Cardiovascular Diseases in Old Age

About this study

Interventions

Behavioral: HIIT program (8 weeks) — Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
Behavioral: MPI program (8 weeks) — Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.

Primary outcomes

Fat oxidation during incremental test (Preintervention (only this one in cross-sectional study) and Postintervention (8 weeks after))
Detrended Fluctuation Analysis (Preintervention and Postintervention (8 weeks after))

Eligibility information

Inclusion Criteria: * Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG) * Aged between 35 and 75 years * Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG) * Not participating in a nutritional/dietary intervention * Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)/week of moderate-vigorous physical activity). * To be capable and willing to provide informed consent * Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff). Exclusion Criteria: * Medical contraindication for being engaged in an exercise. * Additional surgery planned within the intervention * Consuming usually betablocker or any drugs alterning nervous system functioning * History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG) * To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.

Study locations

Faculty of Physical Activity and Sport Sciences, Valencia, Valencia 46010 Spain

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.